In these comments on the Buprenorphine via Telemedicine Proposed Rule, NHeLP urges the DEA to withdraw the proposed rule related to the induction of buprenorphine via telemedicine and continue the expanded telemedicine flexibilities under the Opioid Public Health Emergency.
